Log in with your email address username.


[Department of Error] Department of Error

Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391: 839–49—In the legend of table 1 of this Article (published online first on Jan 5, 2018), the most commonly reported NNRTI at baseline should read “dolutegravir-rilpivirine, n=185 [36%]; CAR, n=189 [37%]”; the most commonly reported protease inhibitor at baseline should read “dolutegravir-rilpivirine, n=58 [11%]; CAR, n=40 [8%]”; and the most commonly reported INSTI at baseline should read “dolutegravir-rilpivirine, n=43 [8%]; CAR, n=44 [9%]”.